Sanofi-aventis video Q&A: CFO Jérôme Contamine Comments on Results for Q3 2010

PARIS PARIS--(BUSINESS WIRE)-- Sanofi-aventis (Paris:SAN) (NYSE:SNY), one of the world’s largest diversified healthcare companies, reports results for the third-quarter of 2010. Jérôme Contamine, Chief Financial Officer of sanofi-aventis, comments on earnings and outlook.

Click to watch the video:

http://www.eurobusinessmedia.com/Sanofi-aventis-video-Q-A-CFO-Jerome-Contamine-comments-on-Q3-2010-results

Topics covered in the interview include:

  • Q3 earnings
  • 2010 full year guidance
  • Lovenox®
  • New launches (Jevtana®, Multaq®)
  • Seasonal flu vaccines
  • Eloxatin®
  • lixisenatide for Diabetes
  • teriflunomide for Multiple Sclerosis
  • US healthcare reform and EU price cuts
  • Cost savings
  • Patent cliff

About sanofi-aventis:

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Company website: http://en.sanofi-aventis.com/home.asp



CONTACT:

Investor Relations : [email protected]
or
Media Relations : [email protected]

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.